133 related articles for article (PubMed ID: 6786741)
1. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.
Omura GA; Greco FA; Birch R
Cancer Treat Rep; 1981; 65(5-6):530-1. PubMed ID: 6786741
[No Abstract] [Full Text] [Related]
2. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
3. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Bruckner HW
Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
[No Abstract] [Full Text] [Related]
4. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
5. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Edmonson JH; Wieand HS; McCormack GW
J Natl Cancer Inst; 1988 Sep; 80(14):1172-3. PubMed ID: 3137360
[No Abstract] [Full Text] [Related]
6. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Weiss RB
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
[No Abstract] [Full Text] [Related]
7. Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
Oldham DS; Wampler GL
Med Pediatr Oncol; 1983; 11(4):297-8. PubMed ID: 6310359
[TBL] [Abstract][Full Text] [Related]
8. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
Sessa C; Bolis G; Valente I; Mangioni C; D'Incalci M
Cancer Treat Rep; 1981; 65(1-2):172-3. PubMed ID: 6784922
[No Abstract] [Full Text] [Related]
10. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
11. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
[No Abstract] [Full Text] [Related]
12. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Rosen GF; Lurain JR; Newton M
Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
[TBL] [Abstract][Full Text] [Related]
13. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Moore DH; Valea F; Crumpler LS; Fowler WC
Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
[TBL] [Abstract][Full Text] [Related]
14. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
Van Amburg AL; Presant CA; Vélez-García E; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
[No Abstract] [Full Text] [Related]
15. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
16. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
17. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
20. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer.
Wharton JT
Cancer Treat Rev; 1991 Mar; 18 Suppl A():15-21. PubMed ID: 1904304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
